Orchestra BioMed Holdings, Inc. OBIO
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1,007.38% | 986.14% | 1,033.89% | 1,169.22% | 6.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,007.38% | 986.14% | 1,033.89% | 1,169.22% | 6.46% |
| Cost of Revenue | -30.96% | -27.31% | -16.82% | -6.86% | 2.07% |
| Gross Profit | 1,085.43% | 1,066.39% | 1,118.04% | 1,267.79% | 6.81% |
| SG&A Expenses | -1.61% | 10.36% | 11.22% | 12.47% | 14.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.09% | 21.23% | 22.32% | 27.41% | 24.39% |
| Operating Income | 18.96% | 18.63% | 20.11% | 19.43% | -25.18% |
| Income Before Tax | 24.17% | 15.31% | 17.61% | 13.64% | -30.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.17% | 15.31% | 17.61% | 13.64% | -30.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.17% | 15.31% | 17.61% | 13.64% | -30.19% |
| EBIT | 18.96% | 18.63% | 20.11% | 19.43% | -25.18% |
| EBITDA | 19.10% | 18.75% | 20.23% | 19.55% | -25.25% |
| EPS Basic | 49.73% | 44.81% | 35.83% | 21.72% | -13.82% |
| Normalized Basic EPS | 43.74% | 43.33% | 34.04% | 21.88% | -16.97% |
| EPS Diluted | 49.73% | 44.81% | 35.83% | 21.72% | -13.82% |
| Normalized Diluted EPS | 43.74% | 43.33% | 34.04% | 21.88% | -16.97% |
| Average Basic Shares Outstanding | 51.68% | 58.02% | 43.78% | 29.55% | 15.61% |
| Average Diluted Shares Outstanding | 51.68% | 58.02% | 43.78% | 29.55% | 15.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |